Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Trifarotene | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Trifarotene | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Trifarotene | hsa00190 | Oxidative phosphorylation | 8.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Trifarotene | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | | Trifarotene | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Trifarotene | hsa00520 | Amino sugar and nucleotide sugar metabolism | 7.87E-03 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Trifarotene | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | | Trifarotene | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Trifarotene | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Trifarotene | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Trifarotene | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 4.30E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | Trifarotene | hsa00730 | Thiamine metabolism | 1.29E-05 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | Trifarotene | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | | Trifarotene | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Trifarotene | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | Trifarotene | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Trifarotene | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Trifarotene | hsa00983 | Drug metabolism - other enzymes | 8.82E-04 | 4 | P20839, P32320, P05164, Q16772 | IMPDH1, CDA, MPO, GSTA3 | More | | Trifarotene | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Trifarotene | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Trifarotene | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Trifarotene | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Trifarotene | hsa03013 | RNA transport | 2.48E-05 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3 | More | | Trifarotene | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Trifarotene | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Trifarotene | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Trifarotene | hsa03060 | Protein export | 1.90E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Trifarotene | hsa03320 | PPAR signaling pathway | 3.78E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Trifarotene | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Trifarotene | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Trifarotene | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Trifarotene | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Trifarotene | hsa04062 | Chemokine signaling pathway | 5.65E-04 | 14 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Trifarotene | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | | Trifarotene | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | | Trifarotene | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Trifarotene | hsa04114 | Oocyte meiosis | 4.51E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Trifarotene | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Trifarotene | hsa04145 | Phagosome | 1.66E-03 | 9 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Trifarotene | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | Trifarotene | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Trifarotene | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Trifarotene | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Trifarotene | hsa04217 | Necroptosis | 2.87E-03 | 8 | P01568, Q13489, P42224, P08238, Q6FI13, Q93077, O43633, Q08752 | IFNA21, BIRC3, STAT1, HSP90AB1, H2AC18; H2AC19, HIST1H2AC, CHMP2A, PPID | More | | Trifarotene | hsa04260 | Cardiac muscle contraction | 4.02E-02 | 2 | P09493, P14927 | TPM1, UQCRB | More | | Trifarotene | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Trifarotene | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Trifarotene | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Trifarotene | hsa04370 | VEGF signaling pathway | 2.47E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Trifarotene | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Trifarotene | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Trifarotene | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Trifarotene | hsa04610 | Complement and coagulation cascades | 1.17E-04 | 1 | P0C0L4 | C4A | More | | Trifarotene | hsa04612 | Antigen processing and presentation | 1.64E-02 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Trifarotene | hsa04613 | Neutrophil extracellular trap formation | 2.34E-03 | 17 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, Q93077, P62807, O60814, P68431, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Trifarotene | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Trifarotene | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Trifarotene | hsa04625 | C-type lectin receptor signaling pathway | 4.80E-02 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | Trifarotene | hsa04640 | Hematopoietic cell lineage | 1.19E-03 | 13 | P13612, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD7, HLA-DOB, TNF | More | | Trifarotene | hsa04650 | Natural killer cell mediated cytotoxicity | 1.27E-06 | 16 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Trifarotene | hsa04657 | IL-17 signaling pathway | 3.94E-03 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Trifarotene | hsa04658 | Th1 and Th2 cell differentiation | 1.50E-07 | 13 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Trifarotene | hsa04659 | Th17 cell differentiation | 2.06E-06 | 16 | P25963, Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.762 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 |
| Trifarotene | hsa04660 | T cell receptor signaling pathway | 4.29E-06 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Trifarotene | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Trifarotene | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Trifarotene | hsa04666 | Fc gamma R-mediated phagocytosis | 2.42E-02 | 5 | P23528, P06396, O14494, P14598, P17252 | CFL1, GSN, PLPP1, NCF1, PRKCA | More | | Trifarotene | hsa04672 | Intestinal immune network for IgA production | 1.62E-02 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Trifarotene | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Trifarotene | hsa04720 | Long-term potentiation | 2.35E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Trifarotene | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Trifarotene | hsa04744 | Phototransduction | 2.80E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Trifarotene | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Trifarotene | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Trifarotene | hsa04912 | GnRH signaling pathway | 4.72E-02 | 4 | Q16539, Q9Y6R4, Q14643, P22694 | MAPK14, MAP3K4, ITPR1, PRKACB | More | | Trifarotene | hsa04914 | Progesterone-mediated oocyte maturation | 7.70E-03 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Trifarotene | hsa04916 | Melanogenesis | 4.80E-02 | 4 | P0DP23, Q9UJU2, P17252, P04628 | CALM1, LEF1, PRKCA, WNT1 | More | | Trifarotene | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Trifarotene | hsa04920 | Adipocytokine signaling pathway | 6.89E-03 | 6 | P33121, Q9Y478, Q04759, Q96RR4, Q9Y4H2, P01375 | ACSL1, PRKAB1, PRKCQ, CAMKK2, IRS2, TNF | More | | Trifarotene | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Trifarotene | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Trifarotene | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.11E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | | Trifarotene | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | | Trifarotene | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Trifarotene | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | Trifarotene | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Trifarotene | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Trifarotene | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Trifarotene | hsa05132 | Salmonella infection | 3.44E-03 | 11 | P51617, P25963, Q9UJU2, Q13489, P10415, O75369, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, NFKBIA, LEF1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Trifarotene | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | Trifarotene | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Trifarotene | hsa05135 | Yersinia infection | 2.58E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | Trifarotene | hsa05140 | Leishmaniasis | 6.34E-04 | 11 | P13612, O75015, P14598, P42224, P13765, O60603, P25963, P01375, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MAPK14, NCF4 | More | | Trifarotene | hsa05144 | Malaria | 1.54E-02 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Trifarotene | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | | Trifarotene | hsa05146 | Amoebiasis | 8.90E-06 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Trifarotene | hsa05152 | Tuberculosis | 5.68E-03 | 9 | Q13488, P0DP23, P48382, O60603, P10415, P13765, P01568, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, BCL2, HLA-DOB, IFNA21, MALT1, IRAK1 | More | | Trifarotene | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Trifarotene | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Trifarotene | hsa05170 | Human immunodeficiency virus 1 infection | 5.72E-04 | 16 | Q02750, P62873, P62879, P16298, P0DP23, Q05397, P17252, O00463, Q14643, P01568, P51617, O60603, P23528, P10415, Q93034, Q9Y6Q5 | MAP2K1, GNB1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, TRAF5, ITPR1, IFNA21, IRAK1, TLR2, CFL1, BCL2, CUL5, AP1M2 | More | | Trifarotene | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | Trifarotene | hsa05202 | Transcriptional misregulation in cancer | 3.44E-04 | 19 | Q12778, Q15532, P41732, P14780, P27930, P14923, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Trifarotene | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Trifarotene | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Trifarotene | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 10 | Q13009, Q12955, Q14643, O75369, P14780, P17252, O60603, P04628, Q13635, P08962 | TIAM1, ANK3, ITPR1, FLNB, MMP9, PRKCA, TLR2, WNT1, PTCH1, CD63 | More | | Trifarotene | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Trifarotene | hsa05212 | Pancreatic cancer | 9.87E-04 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Trifarotene | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | Trifarotene | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Trifarotene | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Trifarotene | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Trifarotene | hsa05320 | Autoimmune thyroid disease | 8.64E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Trifarotene | hsa05321 | Inflammatory bowel disease | 2.22E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Trifarotene | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Trifarotene | hsa05332 | Graft-versus-host disease | 2.76E-02 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | Trifarotene | hsa05410 | Hypertrophic cardiomyopathy | 1.73E-02 | 2 | P26012, P09493 | ITGB8, TPM1 | More | | Trifarotene | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 8.94E-03 | 2 | P15924, P26012 | DSP, ITGB8 | More | | Trifarotene | hsa05415 | Diabetic cardiomyopathy | 1.07E-02 | 6 | P17252, P14598, Q15080, Q16718, O14521, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, GAPDH | More | | |